Breaking News
Start for Free 0
🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screener
Try Stock Screener
Close

Vir Biotechnology Inc (VIR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vir Biotech's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.15 -0.11    -1.19%
21:14:00 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 411,626
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.08 - 9.50
Vir Biotech 9.15 -0.11 -1.19%

Vir Biotech Company Profile

 
Explore the Vir Biotech company profile for core details about Vir Biotech, assess Vir Biotech company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

587

Equity Type

ORD

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Contact Information

Address 1800 Owens Street Suite 900
San Francisco, 94158
United States
Phone 415 906 4324
Fax -

Top Executives

Name Age Since Title
Vicki L. Sato 75 2016 Independent Chairman
George A. Scangos 76 2017 Director
Thomas O. Daniel 70 2017 Scientific Advisor
Robert J. More 56 2016 Independent Director
Sona Saira Ramasastry 48 2019 Independent Director
Jeffrey S. Hatfield 66 2020 Independent Director
Robert Taylor Nelsen 62 2016 Independent Director
Marianne De Backer 55 2023 CEO & Director
Lawrence Corey 76 2016 Co-Founder & Scientific Advisor
Louis J. Picker - - Co-Founder & Scientific Advisor
Klaus Frueh 64 2016 Co-Founder & Scientific Advisor
Jeffrey A. Bluestone 71 - Scientific Advisor
Charles M. Rice - - Scientific Advisor
Susanna Naggie - - Scientific Advisor
Jeffrey V. Ravetch 73 - Scientific Advisor
George H. Poste 80 - Scientific Advisor
Emilio A. Emini 71 2015 Scientific Advisor
Francis V. Chisari - - Scientific Advisor
Norbert W. Bischofberger 68 2024 Independent Director
Charles Elliott Sigal 72 2020 Independent Director
Janet Napolitano 66 2020 Independent Director
Ramy Farid 59 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIR Comments

Write your thoughts about Vir Biotechnology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email